Discovery of a potent and selective COX-2 inhibitor in the alkoxy lactone series with optimized metabolic profile

This publication has 24 references indexed in Scilit:

• Valdecoxib and Parecoxib Sodium
  Drugs of the Future, 2001
• The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor
  Bioorganic & Medicinal Chemistry Letters, 1999
• 2-Heterosubstituted-3-(4-methylsulfonyl)phenyl-5-trifluoromethyl pyridines as selective and orally active cyclooxygenase-2 inhibitors
  Bioorganic & Medicinal Chemistry Letters, 1999
• Novel Molecular Approaches to Analgesia
  Published by Elsevier ,1998
• Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib)
  Journal of Medicinal Chemistry, 1997
• Celecoxib
  Drugs of the Future, 1997
• Chapter 21. Selective Cyclooxygenase-2 Inhibitors
  Published by Elsevier ,1997
• Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): Rationale for selective inhibition and progress to date
  Medicinal Research Reviews, 1996
• Chapter 19. Selective Cyclooxygenase Inhibitors
  Published by Elsevier ,1995
• Human cyclooxygenase-2 cDNA.
  Proceedings of the National Academy of Sciences, 1992